Drug Trial Radar · NCT00110461
Aripiprazole in Children and Adolescents With Bipolar I Disorder
Last checked: Nov 19, 2026Latest source record: May 21, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
296
Actual
Start
Mar 2005
Primary completion
Feb 2007
Study completion Feb 2007
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- May 10, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 10 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to test the safety and efficacy of two doses of aripiprazole in child and adolescent patients with bipolar I disorder, manic or mixed episode with or without psychotic features.
Conditions
- Bipolar Disorder
Interventions
AripiprazoleDrug
Treatment Arm 1 (10 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, and aripiprazole 10 mg QD as the target dose starting on Day 5. Subjects remained on the 10 mg dose for the remainder of the treatment period Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
AripiprazoleDrug
Treatment Arm 2 (30 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, aripiprazole 10 mg QD for 2 days, aripiprazole 15 mg QD for 2 days, aripiprazole 20 mg QD for 2 days, aripiprazole 25 mg QD for 2 days, and aripiprazole 30 mg QD as the target dose starting on Day 13. Subjects remained on the 30 mg dose for the remainder of the treatment period. Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
placeboDrug
Placebo tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Young Mania Rating Scale (Y-MRS) Total Score at Week 4Time frame: Baseline and Week 4
Locations
53 sites in 1 country. Site status is shown where the registry gives one.
Local Institution
Scottsdale, Arizona
Local Institution
Little Rock, Arkansas
Local Institution
National City, California
Local Institution
Orange, California
Local Institution
Pasadena, California
Local Institution
Sacramento, California
Local Institution
San Diego, California
Local Institution
Stanford, California
Local Institution
Washington D.C., District of Columbia
Local Institution
Altamonte Springs, Florida
Local Institution
Hialeah, Florida
Local Institution
Jacksonville, Florida
Local Institution
Miami, Florida
Local Institution
North Miami, Florida
Local Institution
Tampa, Florida
Local Institution
Atlanta, Georgia
Local Institution
Smyrna, Georgia
Local Institution
Boise, Idaho
Local Institution
Chicago, Illinois
Local Institution
Libertyville, Illinois
Local Institution
Indianapolis, Indiana
Local Institution
Kansas City, Kansas
Local Institution
Newton, Kansas
Local Institution
Lexington, Kentucky
Local Institution
Baton Rouge, Louisiana
Local Institution
Lake Charles, Louisiana
Local Institution
Shreveport, Louisiana
Local Institution
Cambridge, Massachusetts
Local Institution
Medford, Massachusetts
Local Institution
Clinton Township, Michigan
Local Institution
Rochester Hills, Michigan
Local Institution
Kansas City, Missouri
Local Institution
St Louis, Missouri
Local Institution
Las Vegas, Nevada
Local Institution
Elmsford, New York
Local Institution
New York, New York
Local Institution
Rochester, New York
Local Institution
Stony Brook, New York
Local Institution
Cincinnati, Ohio
Local Institution
Cleveland, Ohio
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.